Cargando…
The identification of the anthracycline aclarubicin as an effective cytotoxic agent for pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal types of cancer, mainly due to its delayed diagnosis and lack of effective therapeutic options. Therefore, it is imperative to find novel treatment options for PDAC. Here, we tested a series of conventional chemotherapeutics together...
Autores principales: | Brouwer, Thomas P., van der Zanden, Sabina Y., van der Ploeg, Manon, van Eendenburg, Jaap D.H., Bonsing, Bert A., de Miranda, Noel F.C.C., Neefjes, Jacques J., Vahrmeijer, Alexander L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281511/ https://www.ncbi.nlm.nih.gov/pubmed/35324522 http://dx.doi.org/10.1097/CAD.0000000000001283 |
Ejemplares similares
-
Doxorubicin and Aclarubicin: Shuffling Anthracycline
Glycans for Improved Anticancer Agents
por: Wander, Dennis P. A., et al.
Publicado: (2020) -
A Paradoxical Role for Regulatory T Cells in the Tumor Microenvironment of Pancreatic Cancer
por: Brouwer, Thomas, et al.
Publicado: (2022) -
Re-Exploring
the Anthracycline Chemical Space for
Better Anti-Cancer Compounds
por: van Gelder, Merle A., et al.
Publicado: (2023) -
Induction of Fatigue by Specific Anthracycline Cancer Drugs through Disruption of the Circadian Pacemaker
por: Wang, Yumeng, et al.
Publicado: (2022) -
Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines.
por: Lehne, G., et al.
Publicado: (1996)